Alto Neuroscience (ANRO) Non-Current Debt (2023 - 2026)

Alto Neuroscience (ANRO) has 4 years of Non-Current Debt data on file, last reported at $13.9 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt fell 30.37% year-over-year to $13.9 million; the trailing twelve-month figure through Mar 2026 stood at $13.9 million (down 30.37% YoY), and the FY2025 full-year result was $16.2 million, up 57.71% from the prior year.
• Non-Current Debt eased to $13.9 million in Q1 2026, from $16.2 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $20.3 million in Q3 2025 to a low of $9.9 million in Q4 2023.
• A 4-year average of $14.1 million and a median of $12.1 million in 2024 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt jumped 100.22% in 2025 and sank 30.37% in 2026, its largest moves.
• Tracing ANRO's Non-Current Debt over 4 years: stood at $9.9 million in 2023, then advanced by 3.99% to $10.3 million in 2024, then surged by 57.71% to $16.2 million in 2025, then declined by 14.14% to $13.9 million in 2026.
• Business Quant data shows ANRO's Non-Current Debt at $13.9 million in Q1 2026, $16.2 million in Q4 2025, and $20.3 million in Q3 2025.